NULL

NULL

NULL

Summary

A method is described for measuring lipid peroxides
by means of the color reagent of a commercially available test kit
for cholesterol estimation. In principle, this assay makes use of
the oxidative capacity of lipid peroxides to convert iodide to
iodine, whic, can be measured photometrically at 365 nm. cdi-
bration curves were obtained using peroxides such as H202,t-butyl
hydroperoxide, and cumene hydroperoxide. A stoichiometric
relationship W ~ Sobserved between the amount of organic perox-
ides assayed and the concentration of iodine produced. Concen-
trations of lipid peroxides as small as 1 nmol/ml could be mea-
sured. The ability to estimate lipid pemxides of isolated low density
lipoprotein was demonstrated.

ABSTRACT Adult T-cell leukemia (ATL) is an oncogenic disease derived from the HTLV-1-infected T cells and there is no effective therapy known yet. We previously reported that down-regulation of N-myc downstream-regulated gene-2 (NDRG2) expression by DNA Methylation and genetic deletion presents one of the most common alterations in adult T-cell leukemia (ATL) and other various kinds of cancers. A stress-induced NDRG2 suppresses important signaling pathways (PI3K and NF-κB) through the de-phosphorylation of PTEN and NIK as a PP2A recruiter. In this manuscript, we identified protein arginine methyltransferase 5 (PRMT5) as a NDRG2/PP2A binding partner. A NDRG2/PP2A complex down-regulated arginine methyltransferase activity of PRMT5 through de-phosphorylation of the serine and threonine residues and changing its co-localization to the nucleus of ATL cell lines increasing the histone arginine methylation; however, PRMT5 was highly phosphorylated and localized in cytoplasm in NDRG2-deficient ATL.

Aim: To present a case of pyelic fusion anomaly with orthotopic kidneys which is extremely rare. For maximum and only, it was reported twice in the literature. Its diagnosis may be unpredictable and it may predispose to major surgical complications. Case report: An 8-year-old child was diagnosed to have a retrocaval ureter which was repaired through a flank incision. A striking finding of a cut and retracted tubular structure was noted during ureteral dissection. Postoperative contralateral perinephric urinoma developed and drained percutaneously. Then, two surgical explorations were done on the left kidney without detection of a cause for urinary extravasation. The left ureter was atretic during explorations. Kidney autotransplantation and ileal reconstructions seemed difficult solutions and nephrectomy was the final step. Discussion: Pyelic fusion anomaly was reported, mainly, in association to renal fusion anomalies like horseshoe and crossed ectopic kidneys. However, it is the first time to report a case of retrocaval ureter in association to pyelic fusion and normally-located and positioned kidneys. Contralateral urinoma after repair of a retrocaval ureter was a striking complication referred to an underlying crossing left-to-right anomalous pathway. This case represented a surgical trap, because it is an extremely rare and unpredictable association of renal anomalies. Conclusion: Pyelic fusion with orthotopic well-positioned kidneys is an extremely rare renal anomaly. Its association to retrocaval ureter makes it extremely unpredictable, especially, when it is undiagnosed preoperatively.

Background The non-functional ITPArs6051702 gene polymorphism was associated with ribavirin (RBV)-induced reduction in hemoglobin in some populations (1,2). We explored for the first time the relationship between this non-functional variant in addition to the known functional rs1127354 and rs7270101 ones, and the reduction in hematological parameters: hemoglobin, white blood cells (WBCs) and platelets in Egyptian hepatitis patients treated with RBV. Materials and Methods Hundred and twenty-three patients treated with pegylated-interferon (peg-IFN) alpha and RBV have been enrolled. DNA was extracted from buffy coat using Qiagen DNA extraction kits; allelic discrimination was performed for ITPArs6051702, rs1127354 and rs7270101 polymorphisms through real time PCR. Evaluated clinical features were delta hemoglobin, WBCs and platelets reductions at 1, 2, 4, 8 and 12 weeks of therapy. Results We found that the genotypes AC/CC for rs6051702 at week 4 and CA/AA for rs1127354 at week 8 were associated with lower hemoglobin reduction (p = 0.012 and p = 0.019, respectively). Association was found between the presence of at least one variant allele of rs1127354 and less WBCs reduction at week 1 and week 4 (p = 0.038 and 0.020 respectively). Less WBCs reduction at week 1 in AA/AC genotypes of rs7270101 (p = 0.025) has been observed. Multivariate linear regression analysis has been done to detect factors independently associated with hemoglobin reduction at weeks 4, 8 and 12. RBV dose (p = 0.017) and ITPArs6051702 (p = 0.028) were independently associated with hemoglobin reduction at week 4. CA/AA group for rs1127354 (p = 0.005), peg-IFN dose (p = 0.033) and sex (p = 0.036) were independent predictors at week 8. Peg-IFN type (p = 0.001) was the independent predictor at week 12. Conclusions Genotyping of ITPA variants rs6051702 and rs1127354 could be performed to predict anemia before the start of treatment in Egyptian patients. References 1. Fellay J, Thompson J, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010, 464, 405–8. 2. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 2010,40, 1063–71.

Background The non-functional ITPArs6051702 gene polymorphism was associated with ribavirin (RBV)-induced reduction in hemoglobin in some populations (1,2). We explored for the first time the relationship between this non-functional variant in addition to the known functional rs1127354 and rs7270101 ones, and the reduction in hematological parameters: hemoglobin, white blood cells (WBCs) and platelets in Egyptian hepatitis patients treated with RBV. Materials and Methods Hundred and twenty-three patients treated with pegylated-interferon (peg-IFN) alpha and RBV have been enrolled. DNA was extracted from buffy coat using Qiagen DNA extraction kits; allelic discrimination was performed for ITPArs6051702, rs1127354 and rs7270101 polymorphisms through real time PCR. Evaluated clinical features were delta hemoglobin, WBCs and platelets reductions at 1, 2, 4, 8 and 12 weeks of therapy. Results We found that the genotypes AC/CC for rs6051702 at week 4 and CA/AA for rs1127354 at week 8 were associated with lower hemoglobin reduction (p = 0.012 and p = 0.019, respectively). Association was found between the presence of at least one variant allele of rs1127354 and less WBCs reduction at week 1 and week 4 (p = 0.038 and 0.020 respectively). Less WBCs reduction at week 1 in AA/AC genotypes of rs7270101 (p = 0.025) has been observed. Multivariate linear regression analysis has been done to detect factors independently associated with hemoglobin reduction at weeks 4, 8 and 12. RBV dose (p = 0.017) and ITPArs6051702 (p = 0.028) were independently associated with hemoglobin reduction at week 4. CA/AA group for rs1127354 (p = 0.005), peg-IFN dose (p = 0.033) and sex (p = 0.036) were independent predictors at week 8. Peg-IFN type (p = 0.001) was the independent predictor at week 12. Conclusions Genotyping of ITPA variants rs6051702 and rs1127354 could be performed to predict anemia before the start of treatment in Egyptian patients. References 1. Fellay J, Thompson J, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010, 464, 405–8. 2. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 2010,40, 1063–71.

Background The non-functional ITPArs6051702 gene polymorphism was associated with ribavirin (RBV)-induced reduction in hemoglobin in some populations (1,2). We explored for the first time the relationship between this non-functional variant in addition to the known functional rs1127354 and rs7270101 ones, and the reduction in hematological parameters: hemoglobin, white blood cells (WBCs) and platelets in Egyptian hepatitis patients treated with RBV. Materials and Methods Hundred and twenty-three patients treated with pegylated-interferon (peg-IFN) alpha and RBV have been enrolled. DNA was extracted from buffy coat using Qiagen DNA extraction kits; allelic discrimination was performed for ITPArs6051702, rs1127354 and rs7270101 polymorphisms through real time PCR. Evaluated clinical features were delta hemoglobin, WBCs and platelets reductions at 1, 2, 4, 8 and 12 weeks of therapy. Results We found that the genotypes AC/CC for rs6051702 at week 4 and CA/AA for rs1127354 at week 8 were associated with lower hemoglobin reduction (p = 0.012 and p = 0.019, respectively). Association was found between the presence of at least one variant allele of rs1127354 and less WBCs reduction at week 1 and week 4 (p = 0.038 and 0.020 respectively). Less WBCs reduction at week 1 in AA/AC genotypes of rs7270101 (p = 0.025) has been observed. Multivariate linear regression analysis has been done to detect factors independently associated with hemoglobin reduction at weeks 4, 8 and 12. RBV dose (p = 0.017) and ITPArs6051702 (p = 0.028) were independently associated with hemoglobin reduction at week 4. CA/AA group for rs1127354 (p = 0.005), peg-IFN dose (p = 0.033) and sex (p = 0.036) were independent predictors at week 8. Peg-IFN type (p = 0.001) was the independent predictor at week 12. Conclusions Genotyping of ITPA variants rs6051702 and rs1127354 could be performed to predict anemia before the start of treatment in Egyptian patients. References 1. Fellay J, Thompson J, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010, 464, 405–8. 2. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 2010,40, 1063–71.

Background The non-functional ITPArs6051702 gene polymorphism was associated with ribavirin (RBV)-induced reduction in hemoglobin in some populations (1,2). We explored for the first time the relationship between this non-functional variant in addition to the known functional rs1127354 and rs7270101 ones, and the reduction in hematological parameters: hemoglobin, white blood cells (WBCs) and platelets in Egyptian hepatitis patients treated with RBV. Materials and Methods Hundred and twenty-three patients treated with pegylated-interferon (peg-IFN) alpha and RBV have been enrolled. DNA was extracted from buffy coat using Qiagen DNA extraction kits; allelic discrimination was performed for ITPArs6051702, rs1127354 and rs7270101 polymorphisms through real time PCR. Evaluated clinical features were delta hemoglobin, WBCs and platelets reductions at 1, 2, 4, 8 and 12 weeks of therapy. Results We found that the genotypes AC/CC for rs6051702 at week 4 and CA/AA for rs1127354 at week 8 were associated with lower hemoglobin reduction (p = 0.012 and p = 0.019, respectively). Association was found between the presence of at least one variant allele of rs1127354 and less WBCs reduction at week 1 and week 4 (p = 0.038 and 0.020 respectively). Less WBCs reduction at week 1 in AA/AC genotypes of rs7270101 (p = 0.025) has been observed. Multivariate linear regression analysis has been done to detect factors independently associated with hemoglobin reduction at weeks 4, 8 and 12. RBV dose (p = 0.017) and ITPArs6051702 (p = 0.028) were independently associated with hemoglobin reduction at week 4. CA/AA group for rs1127354 (p = 0.005), peg-IFN dose (p = 0.033) and sex (p = 0.036) were independent predictors at week 8. Peg-IFN type (p = 0.001) was the independent predictor at week 12. Conclusions Genotyping of ITPA variants rs6051702 and rs1127354 could be performed to predict anemia before the start of treatment in Egyptian patients. References 1. Fellay J, Thompson J, Ge D, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010, 464, 405–8. 2. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatology Research 2010,40, 1063–71.